USFDA issues warning letter to Cadila Pharmaceuticals
The US Food and Drug Administration (USFDA) has issued a warning letter to Ahmedabad-based Cadila Pharmaceuticals for violating current good manufacturing practice norms at its Ankleshwar plant in Gujarat.
Nov 12, 2014, 17:50 PM ISTFDA warns Cadila Pharma over drug production processes
Cadila Pharmaceuticals is the latest Indian drugmaker to face U.S. regulatory rebuke, as the FDA intensifies its scrutiny of the generic drugmakers.
Nov 12, 2014, 13:53 PM IST